INH14 is a cell permeable inhibitor of IKKα/IKKβ, with IC50s of 8.97 and 3.59 μM, respectively. INH14 inhibits the IKKα/β-dependent TLR inflammatory response. INH14 also inhibits downstream of TAK1/TAB1 and NF-kB pathways. Anti-inflammatory and anti-cancer activity[1]. IKKβ|3.59 μM (IC50)|IKKα|8.97 μM (IC50)
INH14 (5 µg/g, i.p. for 2 hours) reduces lipopeptide-induced inflammation in mice[1]. Animal Model: 8-week old, male, pathogen-free C57BL/6J mice[1]
[1]. Drexel M, et al. INH14, a Small-Molecule Urea Derivative, Inhibits the IKKα/β-Dependent TLR Inflammatory Response. Chembiochem. 2019 Mar 1;20(5):710-717.